Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$29.46 ▼ -0.89
(-2.93%)
MKT CAP: $524.4M • VOL: 254.7K
52W L $11 52W H $38
ROARABLE / RQD
E • 27/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$25
MEDIAN
$33
MEAN
$34
HIGH
$40
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE SRZN TAPE
SRZN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $35.65 | $33.88 | 2025-02-14 | $26.81 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $37.12 | $34.76 | 2025-02-06 | $27.69 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $33.58 | $32.41 | 2025-01-29 | $28.28 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $30.05 | — | 2025-01-17 | $28.87 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $25.92 | $27.99 | 2025-01-09 | $26.22 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $35.06 | $30.64 | 2024-12-18 | $25.63 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $28.58 | $29.75 | 2024-12-04 | $27.40 | -4.3% | 48% | C |